Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's Disease.

Dulai, Parambir S; Wan, Yaping; Huang, Zhongwen; Luo, Michelle

Dulai, Parambir S; Wan, Yaping; Huang, Zhongwen; Luo, Michelle.

Afiliação

Dulai PS; Division of Gastroenterology and Hepatology, Feinberg School of Medicine Northwestern University, Chicago, Illinois, USA.
Wan Y; Takeda Pharmaceuticals U.S.A., Deerfield, Illinois, USA.
Huang Z; Takeda Pharmaceuticals U.S.A., Deerfield, Illinois, USA.
Luo M; Takeda Pharmaceuticals U.S.A., Deerfield, Illinois, USA.

Crohns Colitis 360 ; 4(4): otac048, 2022 Oct.

Article em En | MEDLINE | ID: mdl-36778514

Palavras-chave

Crohn's disease; clinical decision support tool; healthcare resource utilization; vedolizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Crohns Colitis 360 Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google